mOX40L
Atopic Dermatitis, Asthma
DiscoveryActive
Key Facts
About PsiThera
PsiThera is a private, pre-clinical stage biotech aiming to disrupt the immunology market by creating oral 'antibody-in-a-pill' alternatives to injectable biologics. Its core differentiator is the QUAISAR platform, a physics-native, AI-accelerated computational engine designed to model biologically relevant protein motion and reveal transient, druggable pockets on challenging targets. The company is advancing a pipeline of early-stage programs against targets like sTNFα, mOX40L, and TL1A for conditions such as rheumatology, inflammatory bowel disease, and atopic dermatitis.
View full company profileTherapeutic Areas
Other Atopic Dermatitis, Asthma Drugs
| Drug | Company | Phase |
|---|---|---|
| TEV '325 (formerly BD9) | Biolojic Design | Preclinical |
| FYB208 (Dupilumab) | Formycon | Clinical Development |
| BK-600 (Anti-IL-4Rα mAb) | Sichuan Biokin Pharmaceutical | Phase II |